Cargando…
Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies
The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692731/ https://www.ncbi.nlm.nih.gov/pubmed/36430411 http://dx.doi.org/10.3390/ijms232213929 |
_version_ | 1784837341962043392 |
---|---|
author | Gabel, Michael Knauss, Annkathrin Fischer, Dagmar Neurath, Markus F. Weigmann, Benno |
author_facet | Gabel, Michael Knauss, Annkathrin Fischer, Dagmar Neurath, Markus F. Weigmann, Benno |
author_sort | Gabel, Michael |
collection | PubMed |
description | The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in the therapy of human diseases. The limitations of siRNA, such as poor stability, inefficient cell uptake, and undesired immune activation, as well as the inability to specifically reach the target tissue in the body, can be overcome by further developments in the field of nanoparticulate drug delivery. Therefore, types of surface modified siRNA nanoparticles are presented and illustrate how a more efficient and safer distribution of siRNA at the target site is possible by modifying the surface properties of nanoparticles with antibodies. However, the development of such efficient and safe delivery strategies is currently still a major challenge. In consideration of that, this review article aims to demonstrate the function and targeted delivery of siRNA nanoparticles, focusing on the surface modification via antibodies, various lipid- and polymer-components, and the therapeutic effects of these delivery systems. |
format | Online Article Text |
id | pubmed-9692731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96927312022-11-26 Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies Gabel, Michael Knauss, Annkathrin Fischer, Dagmar Neurath, Markus F. Weigmann, Benno Int J Mol Sci Review The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in the therapy of human diseases. The limitations of siRNA, such as poor stability, inefficient cell uptake, and undesired immune activation, as well as the inability to specifically reach the target tissue in the body, can be overcome by further developments in the field of nanoparticulate drug delivery. Therefore, types of surface modified siRNA nanoparticles are presented and illustrate how a more efficient and safer distribution of siRNA at the target site is possible by modifying the surface properties of nanoparticles with antibodies. However, the development of such efficient and safe delivery strategies is currently still a major challenge. In consideration of that, this review article aims to demonstrate the function and targeted delivery of siRNA nanoparticles, focusing on the surface modification via antibodies, various lipid- and polymer-components, and the therapeutic effects of these delivery systems. MDPI 2022-11-11 /pmc/articles/PMC9692731/ /pubmed/36430411 http://dx.doi.org/10.3390/ijms232213929 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gabel, Michael Knauss, Annkathrin Fischer, Dagmar Neurath, Markus F. Weigmann, Benno Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies |
title | Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies |
title_full | Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies |
title_fullStr | Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies |
title_full_unstemmed | Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies |
title_short | Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies |
title_sort | surface design options in polymer- and lipid-based sirna nanoparticles using antibodies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692731/ https://www.ncbi.nlm.nih.gov/pubmed/36430411 http://dx.doi.org/10.3390/ijms232213929 |
work_keys_str_mv | AT gabelmichael surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies AT knaussannkathrin surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies AT fischerdagmar surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies AT neurathmarkusf surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies AT weigmannbenno surfacedesignoptionsinpolymerandlipidbasedsirnananoparticlesusingantibodies |